Sartorius begins building a new, EUR 30-million (US$35.2 million) Cell Culture Technology Center in Ulm, Germany.
Sartorius Stedim Cellca is building a new EUR 30-million (US$35.2 million) Cell Culture Technology Center at Science Park III in Eselsberg, situated at the northwestern scientific hub in Ulm, Germany, the company announced on Sept. 28, 2017, at a groundbreaking ceremony that marked the official start of construction work.
So far, Sartorius Stedim Cellca has been working in a rented building in Laupheim, Germany. The new laboratory and office complex will approximately double the company’s space and is scheduled to be completed by the end of 2019. In addition, relocation to this zone will provide closer proximity to universities and research institutes that are based in Ulm’s Science Park.
Sartorius Stedim Cellca develops cell lines and protein production processes, licenses technologies for the production of proteins, and offers cell culture media. The company has been a part of the biopharma equipment supplier Sartorius Stedim Biotech since 2015 and currently employs around 90 people. Over the medium term, the company plans to extend its workforce to more than 120 people.
Source: Sartorius
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.